Challenges in developing endpoints for type 1 diabetes intervention studies (Q37601387)

21 August 2017

1 reference

title

Challenges in developing endpoints for type 1 diabetes intervention studies (English)

1 reference

21 August 2017

0 references

3

Kevan C Herold

1 reference

21 August 2017

12

Jay S Skyler

1 reference

21 August 2017

13

Jerry P Palmer

1 reference

21 August 2017

Simona Cernea

1

1 reference

21 August 2017

Itamar Raz

2

1 reference

21 August 2017

Boaz Hirshberg

4

1 reference

21 August 2017

Bart O Roep

5

1 reference

21 August 2017

Desmond A Schatz

6

1 reference

21 August 2017

G Alexander Fleming

7

1 reference

21 August 2017

Paolo Pozzilli

8

1 reference

21 August 2017

Randie Little

9

1 reference

21 August 2017

Nanette C Schloot

10

1 reference

21 August 2017

R David G Leslie

11

1 reference

21 August 2017

D-Cure Workshop

14

1 reference

21 August 2017

publication date

1 November 2009

1 reference

Diabetes - Metabolism: Research and Reviews

21 August 2017

published in

1 reference

21 August 2017

volume

25

1 reference

21 August 2017

issue

8

1 reference

21 August 2017

page(s)

694-704

1 reference

A mathematical model for pattern of change in beta-cell reserve and factors affecting residual reserve within the first 2 years of type 1 diabetes.

21 August 2017

cites work

1 reference

A two year observational study of nicotinamide and intensive insulin therapy in patients with recent onset type 1 diabetes mellitus

21 January 2018

1 reference

C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21-22 October 2001.

21 January 2018

1 reference

7 January 2021

Guidelines for Intervention Trials in Subjects With Newly Diagnosed Type 1 Diabetes

1 reference

7 January 2021

Effects of age, duration and treatment of insulin-dependent diabetes mellitus on residual beta-cell function: observations during eligibility testing for the Diabetes Control and Complications Trial (DCCT). The DCCT Research Group

1 reference

7 January 2021

Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial. A randomized, controlled trial. The Diabetes Control and Complications Trial Research Group

1 reference

7 January 2021

Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial

1 reference

7 January 2021

Mixed-meal tolerance test versus glucagon stimulation test for the assessment of beta-cell function in therapeutic trials in type 1 diabetes

1 reference

7 January 2021

Estimation of beta-cell mass by metabolic tests: necessary, but how sufficient?

1 reference

7 January 2021

C-Peptide as a Measure of the Secretion and Hepatic Extraction of Insulin: Pitfalls and Limitations

1 reference

7 January 2021

The limitations to and valid use of C-peptide as a marker of the secretion of insulin

1 reference

7 January 2021

Quantitative study of insulin secretion and clearance in normal and obese subjects

1 reference

7 January 2021

Abnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitus

1 reference

7 January 2021

Insulin release in impaired glucose tolerance: oral minimal model predicts normal sensitivity to glucose but defective response times

1 reference

7 January 2021

Evaluation of HOMA and QUICKI as measures of insulin sensitivity in prepubertal children

1 reference

7 January 2021

Successful islet autotransplantation in humans: functional insulin secretory reserve as an estimate of surviving islet cell mass

1 reference

7 January 2021

INHIBITION OF GLUCOSE-STIMULATED INSULIN RELEASE FROM βTC3 CELLS AND RODENT ISLETS BY AN ANALOG OF FK506

1 reference

7 January 2021

Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes

1 reference

7 January 2021

Effects of autoimmunity and immune therapy on beta-cell turnover in type 1 diabetes

1 reference

7 January 2021

Exendin-4 improves reversal of diabetes in NOD mice treated with anti-CD3 monoclonal antibody by enhancing recovery of beta-cells

1 reference

7 January 2021

Residual beta-cell function in children with IDDM: reproducibility of testing and factors influencing insulin secretory reserve

1 reference

7 January 2021

The rise and fall of insulin secretion in type 1 diabetes mellitus

1 reference

7 January 2021

Increased insulin secretion in puberty: a compensatory response to reductions in insulin sensitivity.

1 reference

7 January 2021

Long-term function (6 years) of islet allografts in type 1 diabetes

1 reference

7 January 2021

The transient effect of strict glycaemic control on B cell function in newly diagnosed Type 1 (insulin-dependent) diabetic patients

1 reference

7 January 2021

Assessment of glycemic control after islet transplantation using the continuous glucose monitor in insulin-independent versus insulin-requiring type 1 diabetes subjects

1 reference

7 January 2021

Metabolic and immune parameters at clinical onset of insulin-dependent diabetes: a population-based study. IMDIAB Study Group. Immunotherapy Diabetes.

1 reference

7 January 2021

Poor beta-cell function after the clinical manifestation of type 1 diabetes in children initially positive for islet cell specific autoantibodies. The Childhood Diabetes in Finland Study Group.

1 reference

7 January 2021

Residual insulin secretion at diagnosis of type 1 diabetes is independently associated with both, age of onset and HLA genotype

1 reference

7 January 2021

Sex- and season-dependent differences in C-peptide levels at diagnosis of immune-mediated type 1 diabetes

1 reference

7 January 2021

Metabolic Factors Affecting Residual Beta Cell Function Assessed by C-Peptide Secretion in Patients with Newly Diagnosed Type 1 Diabetes

1 reference

7 January 2021

Insulin secretion in type 1 diabetes

1 reference

7 January 2021

Glucose and C-peptide changes in the perionset period of type 1 diabetes in the Diabetes Prevention Trial-Type 1.

1 reference

7 January 2021

Clinical manifestations and beta cell function in Swedish diabetic children have remained unchanged during the last 25 years.

1 reference

7 January 2021

Association of IL-1ra and adiponectin with C-peptide and remission in patients with type 1 diabetes

1 reference

7 January 2021

Relation of circulating concentrations of chemokine receptor CCR5 ligands to C-peptide, proinsulin and HbA1c and disease progression in type 1 diabetes

1 reference

7 January 2021

Effect of heat shock protein peptide DiaPep277 on beta-cell function in paediatric and adult patients with recent-onset diabetes mellitus type 1: two prospective, randomized, double-blind phase II trials

1 reference

7 January 2021

A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes

1 reference

7 January 2021

Heat-shock protein peptide DiaPep277 treatment in children with newly diagnosed type 1 diabetes: a randomised, double-blind phase II study

1 reference

7 January 2021

Clinical evidence for the safety of GAD65 immunomodulation in adult-onset autoimmune diabetes

1 reference

7 January 2021

The effects of calcitriol and nicotinamide on residual pancreatic β-cell function in patients with recent-onset Type 1 diabetes (IMDIAB XI)

1 reference

7 January 2021

International comparison of C-peptide measurements

1 reference

7 January 2021

Standardization of C-peptide measurements

1 reference

7 January 2021

Therapy with the hsp60 peptide DiaPep277 in C-peptide positive type 1 diabetes patients

1 reference

7 January 2021

Treatment of new-onset type 1 diabetes with peptide DiaPep277 is safe and associated with preserved beta-cell function: extension of a randomized, double-blind, phase II trial

1 reference

7 January 2021

GAD treatment and insulin secretion in recent-onset type 1 diabetes

1 reference

7 January 2021

Familial and sporadic insulin-dependent diabetes: evidence for heterogeneous etiologies?

1 reference

7 January 2021

Clinical characteristics of children diagnosed with type 1 diabetes through intensive screening and follow-up

1 reference

7 January 2021

A randomized trial of intensive insulin therapy in newly diagnosed insulin-dependent diabetes mellitus

1 reference

7 January 2021

Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years

1 reference

7 January 2021

Correlation between minimal secretory capacity of pancreatic beta-cells and stability of diabetic control

1 reference

7 January 2021

Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus

1 reference

7 January 2021

Simple measures to monitor beta-cell mass and assess islet graft dysfunction.

1 reference

7 January 2021

The stages of type 1A diabetes: 2005.

1 reference

7 January 2021

Prediction of type I diabetes in first-degree relatives using a combination of insulin, GAD, and ICA512bdc/IA-2 autoantibodies

1 reference

7 January 2021

Autoantibodies in type 1 diabetes.

1 reference

7 January 2021

HLA-DPB1*0402 protects against type 1A diabetes autoimmunity in the highest risk DR3-DQB1*0201/DR4-DQB1*0302 DAISY population

1 reference

7 January 2021

Feasibility of genetic and immunological prediction of type I diabetes in a population-based birth cohort

1 reference

7 January 2021

IA-2 antibody isotypes and epitope specificity during the prediabetic process in children with HLA-conferred susceptibility to type I diabetes

1 reference

7 January 2021

Prediction of autoantibody positivity and progression to type 1 diabetes: Diabetes Autoimmunity Study in the Young (DAISY).

1 reference

7 January 2021

Autoantibody appearance and risk for development of childhood diabetes in offspring of parents with type 1 diabetes: the 2-year analysis of the German BABYDIAB Study

1 reference

7 January 2021

Islet autoreactive CD8 T-cells in type 1 diabetes: licensed to kill?

1 reference

7 January 2021

Prevention of type 1 diabetes: the time has come.

1 reference

7 January 2021

Patterns of metabolic progression to type 1 diabetes in the Diabetes Prevention Trial-Type 1.

1 reference

7 January 2021

Altered islet beta-cell function before the onset of type 1 (insulin-dependent) diabetes mellitus

1 reference

7 January 2021

Predictive value of intravenous glucose tolerance test insulin secretion less than or greater than the first percentile in islet cell antibody positive relatives of type 1 (insulin-dependent) diabetic patients

1 reference

7 January 2021

Staging of preclinical type 1 diabetes in siblings of affected children. Childhood Diabetes in Finland Study Group

1 reference

7 January 2021

Type I diabetes mellitus: a predictable autoimmune disease with interindividual variation in the rate of beta cell destruction

1 reference

7 January 2021

Preservation of C-peptide secretion in subjects at high risk of developing type 1 diabetes mellitus--a new surrogate measure of non-progression?

1 reference

7 January 2021

Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. National Diabetes Data Group

1 reference

7 January 2021

Identifiers

DOI

10.1002/DMRR.1002

1 reference

21 August 2017

1 reference